Monitor for updates on the IMPROVE-PAH Phase 3 trial enrollment and any future data readouts, which are the primary value drivers for IKT. The board appointment adds relevant cardiovascular expertise but does not alter the near-term clinical or financial outlook.
Price Chart
Executive Summary
Inhibikase Therapeutics announced the resignation of director Dennis Berman and the appointment of Scott Wasserman, MD, to its Board of Directors, effective October 19, 2026. Dr. Wasserman, a cardiologist with extensive cardiovascular drug development experience at Amgen (including Repatha, Evenity, Aimovig), brings relevant expertise as the company advances its Phase 3 IMPROVE-PAH study of IKT-001 for Pulmonary Arterial Hypertension. This is a routine board refresh with no financial data or guidance provided.
Key Facts
- Dennis Berman resigned from the Board and as Chair of the Compensation Committee, effective October 19, 2026; resignation was not due to any disagreement with the company.
- Scott Wasserman, MD, appointed as a Class III director effective October 19, 2026, and will serve on the Compensation Committee.
- Dr. Wasserman is Chief Medical Officer of Kailera Therapeutics and previously served as VP, Global Development at Amgen, leading cardiovascular/metabolic drug development.
- Dr. Wasserman will receive an initial grant of non-qualified stock options to purchase up to 310,000 shares of common stock plus cash compensation per the Non-Employee Director Compensation Policy.
- The company is a clinical-stage biotech advancing IKT-001, a prodrug of imatinib, in a global Phase 3 study (IMPROVE-PAH) for Pulmonary Arterial Hypertension.
Financial Impact
No financial figures disclosed; director compensation includes options for up to 310,000 shares and standard cash compensation.
Risk Factors
- Phase 3 clinical trial failure or delay for IKT-001 in PAH.
- Clinical-stage biotech with no approved products or recurring revenue; high cash burn risk.
- Dilution from director stock option grants and potential future equity financings.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-426811 |
| Document: d190975dex991.htm | 0001193125-26-426811 |
| Document: 0001193125-26-426811-index-headers.html | 0001193125-26-426811 |
| Document: 0001193125-26-426811-index.html | 0001193125-26-426811 |
| Document: 0001193125-26-426811.txt | 0001193125-26-426811 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $1.66 | awaiting T+20 | — | $1.55 (−6.33%) |
Oct 2, 2026 24d ago | Press Release | $2.00 | awaiting T+20 | — | $1.55 (−22.25%) |
Aug 11, 2026 10w ago | Press Release | $2.40 $2.33 | ▼ −2.92% | ▼ −1.02% | $1.55 (−35.21%) |
Jul 23, 2026 13w ago | 8-K | $2.33 $2.35 | ▲ +0.86% | ▼ −2.45% | $1.55 (−33.26%) |
Jul 17, 2026 14w ago | 3 | $2.23 $2.39 | ▲ +7.17% | ▲ +3.05% | $1.55 (−30.27%) |
Jul 14, 2026 15w ago | 8-K | $2.06 $2.45 | ▼ −18.93% | ▼ −16.44% | $1.55 (+24.51%) |
Jun 29, 2026 17w ago | 8-K | $1.93 $2.33 | ▲ +20.73% | ▲ +21.00% | $1.55 (−19.43%) |
May 12, 2026 23w ago | 8-K | $1.90 $1.67 | ▼ −12.11% | ▼ −11.49% | $1.55 (−18.16%) |
May 12, 2026 23w ago | Press Release | $1.90 $1.67 | ▼ −12.11% | ▼ −11.49% | $1.55 (−18.16%) |
Apr 7, 2026 29w ago | 8-K | $1.76 $1.94 | ▲ +10.23% | ▲ +0.45% | $1.55 (−11.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers